Compare · ASPE vs MRK
ASPE vs MRK
Side-by-side comparison of Aspen Neuroscience Inc. (ASPE) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASPE and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $361.71B, about 999.9x ASPE ($361.7M).
- Over the past year, ASPE is down 6.9% and MRK is up 70.1% - MRK leads by 76.9 points.
- MRK has been more active in the news (19 items in the past 4 weeks vs 10 for ASPE).
- MRK has more recent analyst coverage (25 ratings vs 0 for ASPE).
- Company
- Aspen Neuroscience Inc.
- Merck & Company Inc.
- Price
- -
- -
- Market cap
- $361.7M
- $361.71B
- 1M return
- -6.89%
- +3.04%
- 1Y return
- -6.89%
- +70.05%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 10
- 19
- Recent ratings
- 0
- 25
Aspen Neuroscience Inc.
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest ASPE
- SEC Form SCHEDULE 13D filed by Aspen Neuroscience Inc.
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- Director Thompson Peter A. converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)
- Director Orbimed Advisors Llc converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- Large owner Arch Venture Fund X, L.P. bought $19,999,995 worth of shares (1,333,333 units at $15.00) and converted options into 2,421,589 shares (SEC Form 4)
- Large owner Arch Venture Partners Xiv, L.P. bought $18,000,000 worth of shares (1,200,000 units at $15.00) (SEC Form 4)
- Director Spaventa Andrew converted options into 250,415 shares (SEC Form 4)
- Executive Chair Hasnain Faheem converted options into 36,349 shares (SEC Form 4)
Latest MRK
- SEC Form 10-Q filed by Merck & Company Inc.
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- SEC Form 4 filed by Director Diaz Paul J
- New insider Diaz Paul J claimed ownership of 296 shares (SEC Form 3)
- Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
- Merck downgraded by DZ Bank with a new price target
- Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
- SEC Form 8-K filed by Merck & Company Inc.
- Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
- Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors